Nutrition and health

Objectives:
Studies have shown that creatine supplementation increases intramuscular creatine concentrations, favoring the energy system of phosphagens, which may help explain the observed improvements in high-intensity exercise performance. However, research on physical performance in soccer has shown controversial results, in part because the energy system used is not taken into account. Therefore, this review article (meta-analysis) has been conducted.

Does creatine supplementation improve physical performance in soccer players?

Study design:
This review article included 9 RCTs with a total sample of 168 soccer players (118 males, 50 females) with an average age of 20.3 ± 2.0 years (from 15 to 30 years, as an average for the experimental sample).

The meta-analysis was performed using the random effects model and pooled standardized mean differences (SMD) (Hedges's g).

Results and conclusions:
The investigators found that creatine supplementation did not present beneficial effects on aerobic performance tests [SMD = -0.05, 95% CI = -0.37 to 0.28, p = 0.78] and phosphagen metabolism performance tests (strength, single jump, single sprint and agility tests: SMD = 0.21, 95% CI = -0.03 to 0.45, p = 0.08].

The investigators found, however, creatine supplementation showed beneficial effects on anaerobic performance tests [SMD = 1.23, 95% CI = 0.55 to 1.91, p 0.001].
Concretely, creatine supplementation demonstrated a large and significant effect on Wingate test performance [SMD = 2.26, 95% CI = 1.40 to 3.11, p 0.001].

The investigators concluded creatine supplementation with a loading dose of 20-30 g/day, divided 3-4 times per day, ingested for 6 to 7 days and followed by 5 g/day for 9 weeks or with a low dose of 3 mg/kg/day for 14 days presents positive effects on improving physical performance tests related to anaerobic metabolism, especially anaerobic power, in soccer players.

Original title:
Effects of Creatine Supplementation on Athletic Performance in Soccer Players: A Systematic Review and Meta-Analysis by Mielgo-Ayuso J, Calleja-Gonzalez J, […], Fernández-Lázaro D.

Link:
https://www.mdpi.com/2072-6643/11/4/757/htm

Additional information of El Mondo:
Find here more information/studies about sport nutrition and creatine.

Objectives:
Malaria clinical outcomes vary by erythrocyte characteristics, including ABO blood group, but the effect of ABO blood group on asymptomatic, uncomplicated and placental Plasmodium falciparum (P. falciparum) infection remains unclear. Therefore, this review article has been conducted.

What are the effects of ABO blood group on asymptomatic, uncomplicated and placental Plasmodium falciparum (P. falciparum) infection (malaria infection) in the published literature?

Study design:
This review article included 42 for systematic review and 37 for meta-analysis. Most studies (n = 30) were cross-sectional, 7 were prospective cohort and 5 were case-control studies.

Results and conclusions:
The investigators found meta-analysis showed similar odds of uncomplicated P. falciparum infection among individuals with blood group A [summary OR = 0.96, 95% CI = 0.81-1.12, I2 43.5%, 15 studies], B [summary OR = 0.89, 95% CI = 0.72-1.06, I2 = 57.8%, 15 studies], AB [summary OR = 0.85, 95% CI = 0.59-1.10, I2 = 48.0%, 10 studies] and non-O [summary OR = 0.95, 95% CI = 0.81-1.09, I2 = 55.3%, 17 studies] as compared to those with blood group O.

The investigators found meta-analysis of 4 cohort studies also showed similar risk of uncomplicated P. falciparum infection among individuals with blood group non-O and those with blood group O [summary relative risk = 1.03, 95% CI = 0.84-1.22, I2 = 57.3%].

The investigators found meta-analysis of 6 studies showed similar odds of asymptomatic P. falciparum infection among individuals with blood group A [OR = OR 1.05, 95% CI = 0.84-1.27, I2 = 0.0%], B [OR = 1.03, 95% CI = 0.82-1.24, I2 = 22.2%], AB [OR = 1.23, 95% CI = 0.82-1.64, I2 = 0.0%] and non-O [OR = 1.07, 95% CI = 0.90-1.24, I2 = 23.1%] when compared to those with blood group O.
However, odds of active placental P. falciparum infection was significantly lower in primiparous women with non-O blood groups [OR = 0.46, 95% CI = 0.23-0.69, I2 = 0.0%, 3 studies], particularly in those with blood group A [OR = 0.41, 95% CI = 0.003-0.82, I2 = 1.4%, 4 studies] than those with blood group O.

The investigators concluded that ABO blood group does not affect susceptibility to asymptomatic and/or uncomplicated P. falciparum infection. However, blood group O primiparous women are more susceptible to active placental P. falciparum infection.

Original title:
Effect of ABO blood group on asymptomatic, uncomplicated and placental Plasmodium falciparum infection: systematic review and meta-analysis by Degarege A, Gebrezgi MT, […], Madhivanan P.

Link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346527/

Additional information of El Mondo:
Find more information/studies on food fortification/malnutrition and malaria right here.

Objectives:
The threshold for population-level optimal red blood cell (RBC) folate concentration among women of reproductive age for the prevention of neural tube defects has been estimated at 906 nmol/L. However, the dose-response relationship between folic acid intake and blood folate concentrations is uncharacterized. Therefore, this review article has been conducted.

Is there dose-response relationship between folic acid intake and blood folate concentrations?

Study design:
This review article included 23 articles for red blood cell folate and by 97 articles for serum/plasma folate.

Results and conclusions:
The investigators found in 17 studies red blood cell (RBC) folate concentration increased 1.78 fold [95% CI = 1.66 to 1.93] from baseline to steady-state at 375-570 µg folic acid/day and it took a median of 36 weeks of folic acid intake [95% CI = 27 to 52] to achieve steady-state red blood cell folate concentrations.

The investigators found for every 100 µg/day folic acid intake, serum/plasma folate concentrations increased 11.6% [95% CI = 8.4 to 14.9] from baseline to steady-state, over a median of 13 weeks [95% CI = 10 to 16].

The investigators concluded that there is a dose-response relationship between folic acid intake and changes in blood folate concentrations. At 375-570 µg folic acid/day, red blood cell folate concentrations increase 1.78 fold from baseline to steady-state, over a median of 36 weeks. For every 100 µg/day folic acid intake, serum/plasma folate concentrations increase 11.6% from baseline to steady-state, over a median of 13 weeks. These results can inform how much additional folic acid intake is needed among populations of women whose red blood cell folate concentrations are below the optimal threshold.

Original title:
Systematic Review and Bayesian Meta-analysis of the Dose-response Relationship between Folic Acid Intake and Changes in Blood Folate Concentrations by Crider KS, Devine O, […], Berry RJ.

Link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356991/

Additional information of El Mondo:
Find here more information/studies about pregnancy and folaat (also called folic acid).
 

Objectives:
Although the relationship between dietary intake and serum levels of trans fatty acids and risk of breast cancer has been investigated extensively, findings are inconsistent. Therefore, this review article has been conducted.

Do dietary intake and serum levels of trans fatty acids increase risk of breast cancer?

Study design:
This review article included 6 cohort studies and 1 nested case-control study on total dietary trans fat intake and 1 cohort study and 4 nested case-control studies on serum trans fatty acids.

Participants were apparently healthy aged 26 years or older.

Results and conclusions:
The investigators found no significant relationship between dietary intake of total trans fatty acids and risk of breast cancer [pooled effect size = 1.02, 95% CI = 0.95-1.10, p = 0.403].

The investigators found in 3 effect sizes from 2 cohort studies and 1 nested case-control study, no significant relation between dietary intake of conjugated linoleic acid (CLA) and risk of breast cancer [pooled effect size = 1.05, 95% CI = 0.95-1.17, p = 0.513].

The investigators found based on 5 effect sizes, each additional 1 g/day dietary intake of total trans fats was not significantly associated with risk of breast cancer [RR = 1.00, 95% CI = 0.99-1.01].

The investigators found high serum levels of trans fats were associated with an increased risk of 37% of breast cancer among postmenopausal women [pooled effect size = 1.37, 95% CI = 1.04-1.81, p = 0.02].

The investigators concluded dietary intake of trans fatty acids (also called trans fats) is not associated with risk of breast cancer. However, a significant positive association is seen between serum trans fats and risk of breast cancer in postmenopausal women.

Original title:
Dietary intake and serum levels of trans fatty acids and risk of breast cancer: A systematic review and dose-response meta-analysis of prospective studies by Anjom-Shoae J, Sadeghi O, […], Esmaillzadeh A.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/30954361

Additional information of El Mondo:
Find more information/studies on trans fatty acids consumption, review article/significantly and breastcancer right here.

Objectives:
Exclusive breastfeeding (EBF) rates until 6 months in most low and middle income countries (LMICs) are well below the 90% World Health Organization benchmark. Therefore, this review article has been conducted.

The goal of this review article is to provide evidence on effectiveness of various interventions on exclusive breastfeeding until 6 months in low and middle income countries, compared with standard care.

Study design:
This review article included 67 studies (experimental and observational) with 79 comparisons from 30 low and middle income countries.

Results and conclusions:
The investigators found at 6 months, intervention group infants were more likely to be exclusively breastfed than controls [RR = 2.19, 95% CI = 1.73 to 2.77, I2 = 78.4%, 25 randomized controlled trials].

The investigators found larger effects were obtained from interventions delivered by a combination of professional and laypersons [RR = 3.90, 95% CI = 1.25, 12.21, I2 = 46.7%], in interventions spanning antenatal and post-natal periods [RR = 2.40, 95% CI = 1.70 to 3.38, I2 = 83.6%] and when intensity was between 4 to 8 contacts/sessions [RR = 3.20, 95% CI = 2.30 to 4.45, I2 = 53.8%].

The investigators concluded exclusive breastfeeding until 6 months in low and middle income countries can be improved by a combination of professional and laypersons, interventions spanning antenatal and post-natal periods and when intensity was between 4 to 8 contacts/sessions. Therefore, choice of intervention should be driven by feasibility of delivery in the local context to reduce infant mortality.

Original title:
Improving exclusive breastfeeding in low and middle-income countries: A systematic review by Olufunlayo TF, Roberts AA, […], Jolly K.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/30665273

Additional information of El Mondo:
Find more information/studies on food fortification/malnutrition and breastfeeding right here.

Objectives:
Diverse studies have investigated the impact of prenatal exposure to vitamin D levels on brain development. However, evidence in humans has never been systematically reviewed. Therefore, this meta-analysis (systematic review) has been conducted.

Has a high prenatal vitamin D level positive effect on brain development of the born child?

Study design:
This review article included 25 studies.

Results and conclusions:
The investigators found comparing with the lowest category of prenatal 25(OH)D levels (vitamin D level in blood), the highest prenatal 25(OH)D levels had no significant effects on cognition [pooled beta coefficients = 0.95, 95% CI = -0.03 to 1.93, p = 0.05].

The investigators found comparing with the lowest category of prenatal 25(OH)D levels (vitamin D level in blood), the highest prenatal 25(OH)D levels had no significant effects on psychomotor development [pooled beta coefficients = 0.88, 95% CI = -0.18 to 1.93, p = 0.10].

The investigators found comparing with the lowest category of prenatal 25(OH)D levels (vitamin D level in blood), the highest prenatal 25(OH)D levels significantly reduced risk of ADHD of the born child with 28% [pooled relative risk = 0.72, 95% CI = 0.59 to  0.89, p = 0.002].

The investigators found comparing with the lowest category of prenatal 25(OH)D levels (vitamin D level in blood), the highest prenatal 25(OH)D levels significantly reduced risk of autism-related traits of the born child with 58% [pooled odds ratio = 0.42, 95% CI = 0.25 to 0.71, p = 0.001].

The investigators found there was little evidence for protective effects of high prenatal 25(OH)D for language development and behaviour difficulties of the born child.

The investigators concluded this meta-analysis provides supporting evidence that increased prenatal exposure to 25(OH)D levels is associated with reduced risk of ADHD and autism-related traits of the born child later in life. Associations represent a potentially high public health burden given the current prevalence of vitamin D deficiency and insufficiency among childbearing aging and pregnant women.

Original title:
Neurodevelopmental effects of prenatal vitamin D in humans: systematic review and meta-analysis by García-Serna AM and Morales E.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/30696940

Additional information of El Mondo:
Find more information/studies on vitamin D and pregnancy right here.

 

Objectives:
Is there an association between potato consumption and risk of all-cause, cancer and cardiovascular mortality in adults?

Study design:
This review article included 20  prospective cohort studies with 25,208 cases of all-cause mortality, 4,877 of cancer mortality and 2,366 of cardiovascular mortality.

There was no evidence for publication bias.

Results and conclusions:
The investigators found no significant association between potato consumption and risk of all-cause [RR = 0.90, 95% CI = 0.8 to 1.02, p = 0.096] and cancer [RR = 1.09, 95% CI = 0.96 to 1.24, p = 0.204] mortality.

The investigators found, in addition, no significant linear association between each 100 g/d increments in potato consumption and risk of all-cause [p = 0.7] and cancer [p = 0.09] mortality.
Moreover, nonlinear association between potato consumption and risk of cancer mortality was non-significant [p-nonlinearity = 0.99].

The investigators found, in addition, 2 of 3 studies which examined the association of potato consumption with cardiovascular mortality did not find any significant relationship.

The investigators concluded there is no association between potato consumption and risk of all-cause, cancer and cardiovascular mortality in adults.

Original title:
Potato consumption and risk of all cause, cancer and cardiovascular mortality: a systematic review and dose-response meta-analysis of prospective cohort studies by Darooghegi Mofrad M, Milajerdi A, […], Azadbakht L.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/30638040

Additional information of El Mondo:
Find more information/studies on of potato consumption and elderly right here.
 

Objectives:
Previous meta-analysis showed an inverse association between coffee consumption and all-cause mortality. However, the relationship between caffeinated and decaffeinated coffee consumption and all-cause mortality is inconsistent. Therefore, this review article has been conducted.

Do both caffeinated and decaffeinated coffee consumption reduce all-cause mortality?

Study design:
This review article included 21 cohort studies with a total of 10,103,115 study participants and 240,303 deaths.

Results and conclusions:
The investigators found a nonlinear association between coffee consumption and all-cause mortality [p nonlinearity 0.001].

The investigators found compared with no or rare coffee consumption that 3 cups/d coffee consumption significantly reduced risk of all-cause mortality with 13% [RR = 0.87, 95% CI = 0.84 to 0.89].

The investigators concluded that 3 cups/d coffee consumption reduce risk of all-cause mortality. The reduced risks are similar for caffeinated coffee and decaffeinated coffee.

Original title:
Caffeinated and decaffeinated coffee consumption and risk of all-cause mortality: a dose-response meta-analysis of cohort studies by Li Q, Liu Y, […], Hu D.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/30786114

Additional information of El Mondo:
Find here more information/studies about coffee consumption and chronic diseases.
 

Objectives:
The prevalence of Clostridium difficile infection is rapidly increasing worldwide, but prevalence is difficult to estimate in developing countries where awareness, diagnostic resources and surveillance protocols are limited. Therefore, this review article has been conducted.

The goal of this review article is to determine the current prevalence and incidence density rates of first episodes of Clostridium difficile-associated diarrhea in developing countries.

Study design:
This review article included studies with data providing prevalence or incidence rates of Clostridium difficile-associated diarrhea in developing countries within four regions: Africa-Middle East, developing Asia, Latin America and China.

Results and conclusions:
The investigators found within the regions, the prevalence of Clostridium difficile infection in patients with diarrhea was 15% [95% CI = 13-17%] (including community and hospitalized patients), with no significant difference across regions.

The investigators found the incidence of Clostridium difficile infection in 17 studies including this information was 8.5 per 10,000 patient-days [95% CI = 5.83-12.46]. Prevalence was significantly higher in hospitalized patients versus community patients [p = 0.0227].

The investigators concluded the prevalence estimate of 15% is concerning; however, low awareness and inconsistent diagnostic and surveillance protocols suggest this is markedly underestimated. Enhanced awareness and management of Clostridium difficile infection in patients with diarrhea, along with improvements in infection control and surveillance practices, should be implemented to reduce prevalence of Clostridium difficile-associated diarrhea in developing countries.

Original title:
Clostridium difficile-associated Diarrhea in Developing Countries: A Systematic Review and Meta-Analysis by Curcio D, Cané A, […], Correa J.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/30659481

Additional information of El Mondo:
Find more information/studies on food fortification/malnutrition right here.

Objectives:
Fish consumption and dietary intake of n-3 polyunsaturated acids (PUFAs) may be associated with inflammatory bowel disease (IBD). Therefore, this review article has been conducted.

Is there an association between fish consumption or dietary intake of n-3 polyunsaturated acids (PUFAs) and inflammatory bowel disease risk?

Study design:
This review article included 5 prospective cohort studies and 7 case-control studies with a total sample size of 282,610 participants which 2,002 of them were cases of inflammatory bowel disease (1,061 Crohn's disease (CD) and 937 ulcerative colitis (UC)).

Results and conclusions:
The investigators found fish consumption significantly reduced risk of Crohn's disease with 46% [pooled effect size = 0.54, 95% CI = 0.31-0.96, p = 0.03].

The investigators found there was no relationship between total dietary n-3 PUFAs intake and inflammatory bowel disease risk [pooled effect size = 1.17, 95% CI = 0.80-1.72, p = 0.41].

The investigators found dietary long-chain n-3 PUFAs significantly reduced ulcerative colitis risk with 25% [pooled effect size = 0.75, 95% CI = 0.57-0.98, p = 0.03].

The investigators found no association between dietary α-linolenic acid (ALA) and inflammatory bowel disease risk [pooled effect size = 1.17, 95% CI = 0.63-2.17, p = 0.62].

The investigators concluded fish consumption reduces risk of Crohn's disease and dietary intake of long-chain n-3 PUFAs reduces risk of ulcerative colitis.

Original title:
Dietary intake of fish, n-3 polyunsaturated fatty acids, and risk of inflammatory bowel disease: a systematic review and meta-analysis of observational studies by Mozaffari H, Daneshzad E, […], Azadbakht L.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/30680455

Additional information of El Mondo:
Find here more information/studies about fish consumption, n-3 PUFAs and chronic diseases.
 

Objectives:
Streptococcus pneumoniae is an intermittent commensal organism in the nasopharynx. Colonisation is a prerequisite for disease and malnourished children are especially susceptible to severe infection.

The goal of this review article is to examine published prevalence rates of pneumococcal colonisation in the upper respiratory tract of chronically malnourished children 5 y of age.

Study design:
This review article included 9 observational studies.

Results and conclusions:
The investigators found the prevalence rate of Streptococcus pneumoniae colonisation in malnourished children during the first month of life ranged from 1.0 to 2.0%, increasing at 2 months to 53.9-80.0%. Carriage remained similar from 3 to 60 months at 64.1-88.0%.  

The investigators found meta-analysis showed a pooled prevalence of 67.2% [95% CI = 55.6 to 78.7] in infants 0-3 months of age, 77.9% [95% CI = 68.1 to 87.7] in infants 3-6 months of age and 77.8% [95% CI = 73.9-81.6%] in infants 6-60 months of age.

The investigators concluded in malnourished children the rates of pneumococcal colonisation are higher than in healthy, well-nourished children. Knowledge of colonisation rates can inform policies on vaccination and ancillary interventions during treatment of malnutrition. Future studies should assess the impact of reducing colonisation on disease rates or transmission in these “at-risk” individuals.

Original title:
Nasopharyngeal colonisation with Streptococcus pneumoniae in malnourished children: a systematic review and meta-analysis of prevalence by Smith HC, German E, […], Rylance J.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/30624761

Additional information of El Mondo:
Find more information/studies on food fortification/malnutrition right here.

Objectives:
Is there a relationship between nut consumption and metabolic syndrome (MetS)?

Study design:
This review article included a total of 11 observational studies (6 cross-sectional and 5 prospective cohort studies), which involved a total of 89,224 participants.

Results and conclusions:
The investigators found nut consumption significantly reduced risk of metabolic syndrome with 16% [overall multivariable adjusted RR = 0.84, 95% CI = 0.76-0.92, p  0.001].

The investigators found in subgroup analysis tree nut consumption significantly reduced risk of metabolic syndrome with 3% [RR = 0.97, 95% CI = 0.94-1.00, p =0.04]. However, this reduced risk was not significant in peanuts [RR = 1.01, 95% CI = 0.96-1.06, p = 0.68].

The investigators concluded nut consumption reduces risk of metabolic syndrome. However, this reduced risk is only found in tree nuts, not in peanuts. More well-designed studies with detailed specifications of nut varieties are needed to further elaborate the issues examined in this meta-analysis.

Original title:
Relationship Between Nut Consumption and Metabolic Syndrome: A Meta-Analysis of Observational Studies by Zhang Y and Zhang DZ.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/30716015

Additional information of El Mondo:
Find more information/studies on nut consumption and overweight right here.

Objectives:
Existing studies suggest that dietary vitamins and carotenoids might be associated with a reduced risk of age-related cataract (ARC), although a quantitative summary of these associations is lacking. Therefore, this review article has been conducted.

Do vitamins and carotenoids intake reduce risk of the eye disease age-related cataract? 

Study design:
This review article included 8 RCTs and 12 cohort studies.

Results and conclusions:
The investigators found in cohort studies a significantly reduced risk of 19% [RR = 0.81, 95% CI = 0.71 to 0.92, p = 0.001] of age-related cataract for dietary vitamin A intake.

The investigators found in cohort studies a significantly reduced risk of 20% [RR = 0.80, 95% CI = 0.72 to 0.88, p 0.001] of age-related cataract for dietary vitamin C intake.

The investigators found in cohort studies a significantly reduced risk of 10% [RR = 0.90, 95% CI = 0.80 to 1.00, p 0.049] of age-related cataract for dietary vitamin E intake.

The investigators found in cohort studies a significantly reduced risk of 10% [RR = 0.90, 95% CI = 0.83 to 0.99, p = 0.023] of age-related cataract for dietary β-carotene intake.

The investigators found in cohort studies a significantly reduced risk of 19% [RR = 0.81, 95% CI = 0.75 to 0.89, p 0.001] of age-related cataract for dietary β lutein or zeaxanthin intake.

The investigators found in RCTs compared with the placebo, a non-significantly reduced risk of 3% [RR = 0.97, 95% CI = 0.91 to 1.03, p 0.262] of age-related cataract for vitamin E supplementation.
Non-significantly because RR of 1 was found in the 95% CI of 0.91 to 1.03. RR of 1 means no risk/association.

The investigators found in RCTs compared with the placebo, a non-significantly reduced risk of 1% [RR = 0.99, 95% CI = 0.92 to 1.07, p 0.820] of age-related cataract for β-carotene supplementation.

The investigators found in dose-response analysis of cohort studies a significantly reduced risk of 26% [RR = 0.74, 95% CI = 0.67 to 0.80, p 0.001] of age-related cataract for every 10-mg/d increase in dietary lutein or zeaxanthin intake.

The investigators found in dose-response analysis of cohort studies a significantly reduced risk of 18% [RR = 0.82, 95% CI = 0.74 to 0.91, p 0.001] of age-related cataract for every 500-mg/d increase in dietary vitamin C intake.

The investigators found in dose-response analysis of cohort studies a significantly reduced risk of 8% [RR = 0.92, 95% CI = 0.88 to 0.96, p 0.001] of age-related cataract for every 5-mg/d increase in dietary β-carotene intake.

The investigators found in dose-response analysis of cohort studies a significantly reduced risk of 6% [RR = 0.94, 95% CI = 0.90 to 0.98, p 0.001] of age-related cataract for every 5 mg/d increase in dietary vitamin A intake.

The investigators concluded dietary intake of vitamin A (at least 5 mg per day), vitamin C (at least 500 mg per day), vitamin E, β-carotene (at least 5 mg per day) and lutein or zeaxanthin intake (at least 10 mg per day) reduce risk of age-related cataract.

Original title:
Dietary vitamin and carotenoid intake and risk of age-related cataract by Jiang H, Yin Y, […], Ma L.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/30624584

Additional information of El Mondo:
Find more information/studies on of vitamin A, vitamin C, vitamin E, β-carotene and elderly right here.
 

Objectives:
The goal of this review article is to quantify the risk of P vivax parasitaemia after treatment of Plasmodium falciparum with commonly used antimalarial drugs to assess the potential benefits of radical cure for all patients with uncomplicated malaria in co-endemic regions.

Study design:
This review article included 153 studies with a total of 31,262 patients from 323 site-specific treatment groups (from 21 countries): 130 (85%) studies were from the Asia-Pacific region, 16 (10%) from the Americas and 7 (5%) from Africa.

Data for outcomes could be extracted from 106 studies for day 28, 58 studies for day 42 and 12 studies for day 63.

Studies were included if the presence or absence of P vivax parasitaemia was recorded after treatment.
The primary outcome was the risk of P vivax parasitaemia between day 7 and day 42 after initiation of antimalarial treatment for P falciparum, with the pooled risk calculated by random-effects meta-analysis.

There was substantial heterogeneity between study populations.
The mean or median age ranged from 2.9 years to 38.4 years.
Mean or median baseline parasitaemia ranged from 518 to 68 178 parasites per μL.
The prevalence of P falciparum gametocytes at baseline ranged from 0% to 52% and the mean or median baseline haemoglobin ranged from 7.8 g/dL to 14.3 g/dL.

Results and conclusions:
The investigators found the risk of P vivax parasitaemia by day 42 was 5.6% [95% CI = 4.0-7.4, I2 = 92.0%, 117 estimates].

The investigators found the risk of P vivax parasitaemia was 6.5% [95% CI = 4.6-8.6] in regions of short relapse periodicity compared with 1.9% [95% CI = 0.4-4.0] in regions of long periodicity and was greater after treatment with a more rapidly eliminated ACT: 15.3% [95% CI = 5.1-29.3] for artemether-lumefantrine compared with 4.5% [95% CI = 1.2-9.3] for dihydroartemisinin-piperaquine and 5.2% [95% CI = 2.9-7.9] for artesunate-mefloquine.

The investigators found recurrent parasitaemia was delayed in patients treated with ACTs containing mefloquine or piperaquine compared with artemether-lumefantrine, but by day 63 the risk of vivax parasitaemia was more than 15% for all ACTs assessed.

The investigators concluded meta-analysis of 31,262 patients treated for falciparum malaria shows a high risk of subsequent P vivax parasitaemia across a range of co-endemic settings. P vivax parasitaemia occurred more frequently after treatment with rapidly eliminated drugs and in regions with short relapse periodicity. The risk was particularly apparent after treatment with artemether-lumefantrine [15.3% by day 42], accounting for more than half of all recurrent parasitaemias.
These findings suggest that in some regions co-endemic for both P falciparum and P vivax, the introduction of a universal policy of radical cure for all patients with uncomplicated malaria has potential to prevent recurrent parasitaemia, reduce ongoing transmission and enhance malaria elimination efforts.

Original title:
Risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysis by Commons RJ, Simpson JA, […], Price RN.

Link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300482/

Additional information of El Mondo:
Find more information/studies on food fortification/malnutrition and malaria right here.

Objectives:
Epidemiological studies focusing on the association between folate and breast cancer risk reported inconsistent findings. Therefore, this review article has been conducted.

Does dietary folate intake reduce breast cancer risk?

Study design:
This review article included a total of 23 prospective cohort studies involving 41,516 cases (=women with breast cancer) among 1,171,048 individuals.

Results and conclusions:
The investigators found dietary folate intake significantly reduced risk of oestrogen-receptor-negative breast cancer with 12% [pooled risk ratio = 0.88, 95% CI = 0.78-1.00].

The investigators found dietary folate intake significantly reduced risk of oestrogen-receptor-negative/progesterone-receptor-negative breast cancer with 18% [pooled risk ratio = 0.82, 95% CI = 0.68-0.97].

The investigators found an increment of dietary folate intake of 100 μg per day was associated with a deceased risk of oestrogen-receptor-negative breast cancer with 6% [RR = 0.94, 95% CI = 0.88-0.99].

The investigators found an increment of dietary folate intake of 100 μg per day was associated with a deceased risk of oestrogen-receptor-negative/progesterone-receptor-negative breast cancer with 10% [RR = 0.90, 95% CI = 0.85-0.97].

The investigators found high dietary folate intake significantly reduced breast cancer risk in premenopausal women with 6% [RR = 0.94, 95% CI = 0.88-1.00].

The investigators found high dietary folate intake significantly reduced breast cancer risk in women with moderate or high levels of alcohol consumption with 18% [RR = 0.82, 95% CI = 0.72-0.94].

The investigators concluded that at least 100 μg per day dietary folate intake, reduce both oestrogen-receptor-negative and oestrogen-receptor-negative/progesterone-receptor-negative breast cancer, particularly among premenopausal women and women with moderate or high levels of alcohol consumption.

Original title:
Folate intake and the risk of breast cancer: an up-to-date meta-analysis of prospective studies by Zeng J, Wang K, [...], Chang H.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/30647438

Additional information of El Mondo:
Find more information/studies on folate consumption, review article/significantly and breast cancer right here.

Objectives:
Evidence from randomized controlled trials (RCTs) suggests that viscous dietary fiber may offer beneficial effects on glycemic control and, thus, an improved cardiovascular disease risk profile. Therefore, this review article (meta-analysis) has been conducted.

Does viscous dietary fiber supplementation improve glycemic control in type 2 diabetes?

Study design:
This review article included 28 RCTs of ≥3 weeks in duration that assessed the effects of viscous fiber on markers of glycemic control in type 2 diabetes with a total of 1,394 participants.

Results and conclusions:
The investigators found that viscous fiber at a median dose of ∼13.1 g/day significantly reduced HbA1c in type 2 diabetes [MD = -0.58%, 95% CI = -0.88 to -0.28, p = 0.0002] compared with control and in addition to standard of care.

The investigators found that viscous fiber at a median dose of ∼13.1 g/day significantly reduced fasting blood glucose in type 2 diabetes [MD = -0.82 mmol/L, 95% CI = -1.32 to -0.31, p = 0.001] compared with control and in addition to standard of care. 

The investigators found that viscous fiber at a median dose of ∼13.1 g/day significantly reduced HOMA-insulin resistance in type 2 diabetes [MD = -1.89, 95% CI = -3.45 to -0.33, p = 0.02] compared with control and in addition to standard of care.

The investigators found the certainty of evidence was graded moderate for HbA1c, fasting glucose, fasting insulin and HOMA-IR and low for fructosamine.

The investigators concluded that 13.1 g/day viscous fiber supplements improve conventional markers of glycemic control beyond usual care and should be considered in the management of type 2 diabetes.

Original title:
Should Viscous Fiber Supplements Be Considered in Diabetes Control? Results From a Systematic Review and Meta-analysis of Randomized Controlled Trials by Jovanovski E, Khayyat R, […], Vuksan V.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/30617143

Additional information of El Mondo:
Find more information/studies on diabetes and dietary fiber right here.

Objectives:
Is there an association between vitamin D and Parkinson's disease risk?

Study design:
This review article included 8 studies.

Results and conclusions:
The investigators found when compared with normal controls, 25-hydroxyvitamin D insufficiency (30 ng/mL) significantly increased risk of Parkinson's disease with 77% [OR = 1.77, 95% CI = 1.29 to 2.43, p 0.001].

The investigators found when compared with normal controls, 25-hydroxyvitamin D deficiency (20 ng/mL) significantly increased risk of Parkinson's disease with 155% [OR = 2.55, 95% CI = 1.98 to 3.27, p 0.001].

The investigators found 15 minutes/week sunlight exposure significantly decreased risk of Parkinson's disease with 98% [OR = 0.02, 95% CI = 0.00 to 0.10, p 0.001].

The investigators found the use of vitamin D supplements was effective in increasing 25-hydroxyvitamin D levels [SMD = 1.79, 95% CI = 1.40 to 2.18, p 0.001], but had no significant effect on motor function [MD = -1.82, 95% CI = -5.10 to 1.45, p = 0.275] in patients with Parkinson's disease.

The investigators concluded that insufficiency and deficiency of 25-hydroxyvitamin D (vitamin D in blood) and reduced exposure to sunlight increase risk of Parkinson's disease. However, vitamin D supplements show no significant benefits in improving motor function for patients with Parkinson's disease.

Original title:
The Association Between Vitamin D Status, Vitamin D Supplementation, Sunlight Exposure, and Parkinson's Disease: A Systematic Review and Meta-Analysis by Zhou Z, Zhou R, [...], Li K.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/30672512

Additional information of El Mondo:
Find here more information/studies about vitamin D and chronic diseases.
 

Objectives:
Low fruit and vegetable intakes are recognized risk factors for noncommunicable diseases. Therefore, this review article has been conducted.

Do fruit or vegetables intakes reduce noncommunicable diseases, likes cancer, coronary heart disease and all-cause mortality?

Study design:
This review article included 64 reports investigating 98 risk-disease pairs. 56 pairs from 39 reports were assessed as statistically significant, involving 29 burden of diseases.

Results and conclusions:
The investigators found in linear dose analysis for each 100 g/day increase in fruit intakes a significantly reduced risk of 44% [RR = 0.56, 95% CI = 0.42 to 0.74] for esophageal cancer.
Significant means that there is an association with a 95% confidence.

The investigators found in linear dose analysis for each 100 g/day increase in fruit intakes a significantly reduced risk of 28% [RR = 0.72, 95% CI = 0.59 to 0.87] for mouth, pharynx and larynx cancer.

The investigators found in nonlinear dose analysis for the first 100 g/day increase in fruit intakes a significantly reduced risk of 14% [RR = 0.86, 95% CI = 0.84 to 0.88] for stroke.

The investigators found in nonlinear dose analysis for the first 100 g/day increase in fruit intakes a significantly reduced risk of 11% [RR = 0.89, 95% CI = 0.88 to 0.90] for all-cause mortality.

The investigators found in linear dose analysis for each 100 g/day increase in vegetable intakes a significantly reduced risk of 12% [RR = 0.88, 95% CI = 0.80 to 0.95] for renal cell cancer.

The investigators found in linear dose analysis for each 100 g/day increase in vegetable intakes a significantly reduced risk of 11% [RR = 0.89, 95% CI = 0.84 to 0.95] for non-Hodgkin lymphoma.

The investigators found in nonlinear dose analysis for the first 100 g/day increase in vegetable intakes a significantly reduced risk of 14% [RR = 0.86, 95% CI = 0.84 to 0.89] for coronary heart disease.

The investigators found in nonlinear dose analysis for the first 100 g/day increase in vegetable intakes a significantly reduced risk of 13% [RR = 0.87, 95% CI = 0.84 to 0.90] for all-cause mortality.

The investigators found in nonlinear dose analysis clear increases in protective associations were observed with the first 200 g/day of fruit or vegetable intakes, whereas little further increase or even decrease in protective associations were reported beyond 300 g/day intakes.

The investigators found canned fruit intakes were positively associated with all-cause and cardiovascular disease mortality.

The investigators found pickled vegetable intakes were positively associated with stomach cancer.

The investigators concluded that 100-300 g/day of fruit or vegetables intakes reduce certain cancers, coronary heart disease and all-cause mortality. These findings support existing recommendations for fruit and vegetable intakes. Current comparative risk assessments might significantly underestimate the protective associations of fruit and vegetable intakes.

Original title:
The Associations of Fruit and Vegetable Intakes with Burden of Diseases: A Systematic Review of Meta-Analyses by Yip CSC, Chan W and Fielding R.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/30639206

Additional information of El Mondo:
Find more information/studies on fruit and vegetable consumption, coronary heart disease and cancer right here.

Objectives:
Approximately 600 million children of preschool and school age are anaemic worldwide. It is estimated that at least half of the cases are due to iron deficiency. Point-of-use fortification of foods with micronutrient powders (MNP) has been proposed as a feasible intervention to prevent and treat anaemia. It refers to the addition of iron alone or in combination with other vitamins and minerals in powder form, to energy-containing foods (excluding beverages) at home or in any other place where meals are to be consumed. MNPs can be added to foods either during or after cooking or immediately before consumption without the explicit purpose of improving the flavour or colour. Therefore, this review article (meta-analysis) has been conducted.

The aim of this review article is to assess the effects of point-of-use fortification of foods with iron-containing MNP alone, or in combination with other vitamins and minerals on nutrition, health and development among children at preschool (24 to 59 months) and school (5 to 12 years) age, compared with no intervention, a placebo or iron-containing supplements.

Study design:
This review article included 13 trials (RCTs and quasi-RCTs) involving 5,810 participants from Latin America, Africa and Asia, of which 6 ongoing/unpublished trials.
All trials compared the provision of MNP for point-of-use fortification with no intervention or placebo. No trials compared the effects of MNP versus iron-containing supplements (as drops, tablets or syrup).
The sample sizes in the included trials ranged from 90 to 2193 participants. 6 trials included participants younger than 59 months of age only, 4 included only children aged 60 months or older and 3 trials included children both younger and older than 59 months of age.

The iron doses varied from 2.5 mg to 30 mg of elemental iron. 4 trials reported giving 10 mg of elemental iron as sodium iron ethylenediaminetetraacetic acid (NaFeEDTA), chelated ferrous sulphate or microencapsulated ferrous fumarate. 3 trials gave 12.5 mg of elemental iron as microencapsulated ferrous fumarate. 3 trials gave 2.5 mg or 2.86 mg of elemental iron as NaFeEDTA. 1 trial gave 30 mg and 1 trial provided 14 mg of elemental iron as microencapsulated ferrous fumarate, while 1 trial gave 28 mg of iron as ferrous glycine phosphate.

Micronutrient powders contained from 2 to 18 vitamins and minerals

Results and conclusions:
The investigators found in comparison with receiving no intervention or a placebo, children receiving iron-containing micronutrient powders for point-of-use fortification of foods had a significantly lower risk of 34% for anaemia prevalence [prevalence ratio = 0.66, 95% CI = 0.49 to 0.88, 10 trials, 2,448 children; moderate-quality evidence].

The investigators found in comparison with receiving no intervention or a placebo, children receiving iron-containing micronutrient powders for point-of-use fortification of foods had a significantly lower risk of 65% for iron deficiency [prevalence ratio = 0.35, 95% CI = 0.27 to 0.47, 5 trials, 1,364 children; moderate-quality evidence].

The investigators found in comparison with receiving no intervention or a placebo, children receiving iron-containing micronutrient powders for point-of-use fortification of foods had higher haemoglobin levels [mean difference MD = 3.37 g/L, 95% CI = 0.94 to 5.80, 11 trials, 2,746 children; low-quality evidence].

The investigators found in comparison with receiving no intervention or a placebo, no effect on diarrhoea among children receiving iron-containing micronutrient powders for point-of-use fortification of foods was observed [risk ratio = 0.97, 95% CI = 0.53 to 1.78, 2 trials, 366 children; low-quality evidence].

The investigators concluded point-of-use fortification of foods with micronutrient powders containing iron (2.5 mg to 30 mg of elemental iron) reduces anaemia and iron deficiency in preschool- and school-age children. However, information on mortality, morbidity, developmental outcomes and adverse effects is still scarce.

Original title:
Point-of-use fortification of foods with micronutrient powders containing iron in children of preschool and school-age by De-Regil LM, Jefferds MED and Peña-Rosas JP.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/29168569

Additional information of El Mondo:
Find more information/studies on food fortification/malnutrition, study design/meta-analysis/significant and iron right here.

Objectives:
Artemisinin combination therapies (ACTs), the most efficacious antimalarials available, are the recommended first-line treatment for Plasmodium falciparum malaria except in the first trimester of pregnancy. Animal embryotoxicity data and the scarcity of safety data in human pregnancies, have prevented artemisinin derivatives from being recommended for malaria treatment in the first trimester except in lifesaving circumstances. Therefore, this review article (meta-analysis) has been conducted.

The aim of this review article is to compare the risk of miscarriage, stillbirth and major congenital anomaly (primary outcomes) among first-trimester pregnancies treated with artemisinin derivatives versus quinine or no antimalarial treatment.

Study design:
This review article included 5 prospective observational studies involving 30,618 pregnancies; 4 from sub-Saharan Africa (n = 6,666 pregnancies, 6 sites) and 1 from Thailand (n = 23,952).

Results and conclusions:
The investigators found no difference in the risk of miscarriage associated with the use of artemisinins anytime during the first trimester (n = 37/671) compared with quinine [adjusted hazard ratio = 0.73, 95% CI = 0.44 to 1.21, I2 = 0%, p = 0.228, n = 96/945].

The investigators found pregnancies treated with quinine during the first trimester were associated with significantly increased risk of 48% of miscarriage compared with pregnancies not treated with an antimalarial [adjusted hazard ratio = 1.48, 95% CI = 1.18 to 1.86]. However, in the sensitivity analysis the association between miscarriage and first-trimester quinine treatment compared with no antimalarial treatment was no longer significant when data from Thailand were omitted [adjusted hazard ratio = 2.12, 95% CI = 0.76 to 5.94, p = 0.153].
Significant because RR of 1 was not found in the 95% CI of 1.18 to 1.86. RR of 1 means no risk/association.

The investigators found pregnancies treated with artemisinins during the first trimester were not associated with an increased risk of miscarriage compared with pregnancies not treated with an antimalarial [adjusted hazard ratio = 1.16, 95% CI = 0.81 to 1.66].
Not associated because adjusted hazard ratio of 1 was found in the 95% CI of 0.81 to 1.66. Adjusted hazard ratio of 1 means no risk/association.

The investigators found no difference in the risk of stillbirth associated with the use of artemisinins anytime during the first trimester (n = 10/654) compared with quinine [adjusted hazard ratio = 0.29, 95% CI = 0.08 to 1.02, p = 0.053, n = 11/615].

The investigators found neither treatment with an artemisinin nor quinine was associated with an increased risk of stillbirths compared to pregnancies without any antimalarial treatment in the first trimester [adjusted hazard ratio = 0.65, 95% CI = 0.34 to 1.23 and adjusted hazard ratio = 1.35, 95% CI = 0.69 to 2.65, respectively].

The investigators found no difference in the risk of miscarriage and stillbirth combined (pregnancy loss) associated with the use of artemisinins anytime during the first trimester (n = 10/654) compared with quinine [adjusted hazard ratio = 0.58, 95% CI = 0.36 to 1.02, p = 0.099]. 

The investigators found the prevalence of major congenital anomalies was similar for first-trimester artemisinin [1.5%, 95% CI = 0.6% to 3.5%] and quinine exposures [1.2%, 95% CI = 0.6% to 2.4%].

The investigators concluded that first-trimester use of artemisinin derivatives is not associated with an increased risk of miscarriage or stillbirth compared to quinine. The data to date also indicate no difference in the prevalence of major anomalies between treatment groups in early pregnancy, although the numbers of major anomalies were small. Three-day artemisinin combination therapy (ACT) regimens are currently recommended to treat malaria in the second and third trimester. Expanding ACT recommendations to include the first trimester may outweigh the adverse outcomes of partially treated malaria due to poor adherence to 7 days oral quinine regimens in early pregnancy.

Original title:
First-trimester artemisinin derivatives and quinine treatments and the risk of adverse pregnancy outcomes in Africa and Asia: A meta-analysis of observational studies by Dellicour S, Sevene E, […], Stergachis A.

Link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412992/

Additional information of El Mondo:
Find more information/studies on food fortification/malnutrition, pregnancy and study design/meta-analysis/significant right here.

Objectives:
There is no agreed standard method to assess the efficacy of antimalarial drugs for uncomplicated falciparum in pregnancy despite an increased risk of adverse outcomes for the mother and the fetus. Therefore, this review article (meta-analysis) has been conducted.

The aim of this review article is to update the currently available efficacy data of artemisinin-based treatments (ABT) and quinine-based treatments (QBT) from both observational and interventional cohort studies in all trimesters with uncomplicated falciparum malaria.  

Study design:
This review article included 48 studies with 7,279 treated Plasmodium falciparum episodes, of which 22 RCTs comparing two or more treatment regimens.
14 studies included women treated with QBT, 40 studies included ABT and 6 studies included both. Altogether, 6244 and 1035 episodes were treated with ABT or QBT, respectively.

First trimester women were included in 12 studies none of which were, however, RCTs of ABT treated.

Results and conclusions:
The investigators found that while polymerase chain reaction (PCR) was used in 24 studies for differentiating recurrence, the assessment and reporting of treatment efficacy was heterogeneous.

The investigators found when the same definition could be applied, PCR-corrected treatment failure of ≥ 10% at any time points was observed in 3/30 ABT and 3/7 QBT arms.

The investigators found in 5 RCTs compared ABT and QBT that the risk of treatment failure was significantly lower in ABT than in QBT [risk ratio = 0.22, 95% CI = 0.07-0.63], although the actual drug combinations and outcome endpoints were different. There was no evidence for asymmetry of the funnel plot suggesting publication bias [p = 0.7].
However, none of these 5 RCTs included pregnant women in the first trimester.

The investigators concluded that efficacy studies in pregnancy are not only limited in number but use varied methodological assessments. In 5 RCTs with comparable methodology, ABT resulted in higher efficacy than QBT in the second and third trimester of pregnancy. Individual patient data meta-analysis can include data from observational cohort studies and could overcome some of the limitations of the current assessment given the paucity of data in this vulnerable group.

Original title:
Systematic literature review and meta-analysis of the efficacy of artemisinin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: methodological challenges by Saito M, Gilder ME, […], Guérin PJ.

Link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729448/

Additional information of El Mondo:
Find more information/studies on food fortification/malnutrition, pregnancy and study design/meta-analysis/significant right here.

Objectives:
Atovaquone/proguanil, registered as Malarone®, is a fixed-dose combination recommended for first-line treatment of uncomplicated Plasmodium falciparum malaria in non-endemic countries and its prevention in travellers. Mutations in the cytochrome bc1 complex are causally associated with atovaquone resistance. Therefore, this review article (meta-analysis) has been conducted.

The aim of this review article is to assess the clinical efficacy of atovaquone/proguanil treatment of uncomplicated malaria and examines the extent to which codon 268 mutation in cytochrome b influences treatment failure and recrudescence based on published information.

Study design:
This review article included 27 P. falciparum studies with 1960 patients, of whom 1695 were treated and followed up to 28 days (86.5%). A total of 1640 patients were successfully treated up to 28 days, 83.7% of the 1960 original patients and 96.8% of the 1695 treated and followed-up patients. Most of the 27 studies were of low methodological quality, being small and having between 18 and 253 participants receiving atovaquone/proguanil.

14 of the 27 studies were RCT designed to test the efficacy of atovaquone/proguanil or used atovaquone/proguanil as a control treatment and participants of these made up only 55% of the total participants.

Results and conclusions:
The investigators found that atovaquone/proguanil treatment efficacy was 89%-98% for P. falciparum malaria (from 27 studies including between 18 and 253 patients in each case) and 20%-26% for Plasmodium vivax malaria (from 1 study including 25 patients).

The investigators found that the in vitro P. falciparum phenotype of atovaquone resistance was an IC50 value >28 nM.

The investigators found in case report analyses that recrudescence in a patient presenting with parasites carrying cytochrome b codon 268 mutation would occur on average at day 29 [95% CI = 22-35], 19 [95% CI = 7-30] days longer than if the mutation is absent.

The investigators concluded that atovaquone/proguanil therapy is comparable in efficacy to ACT used in treating uncomplicated malaria. Late treatment failure is likely to be associated with a codon 268 mutation in cytochrome b, though recent evidence from animal models suggests these mutations may not spread within the population. However, early treatment failure is likely to arise through alternative mechanisms, requiring further investigation.

Original title:
Clinical implications of Plasmodium resistance to atovaquone/proguanil: a systematic review and meta-analysis by Staines HM, Burrow R, […], Krishna S.

Link:
https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dkx431/4693708

Additional information of El Mondo:
Find more information/studies on food fortification/malnutrition and study design/meta-analysis/significant right here.

Objectives:
What is the relationship between serum, dietary and urinary potassium and the risk of type 2 diabetes mellitus (T2DM)?  

Study design:
This review article included 8 prospective cohort studies involved 5,053 type 2 diabetes mellitus cases among 119,993 individuals.
The follow-up durations were from 5 to 18.1 years with a baseline age range from 18 to 95 years.
Serum potassium was measured using the ion-selective electrode method. Dietary potassium was estimated from food frequency questionnaire (FFQ). Urinary potassium samples were analyzed by potentiometric methods.
Most of the included studies provided risk estimates adjusted for age, sex, race, BMI and family history of diabetes.

Results and conclusions:
The investigators found in 5 studies involving 28,944 individuals and 3,849 type 2 diabetes mellitus cases, a non-significantly reduced risk of 21% [summary RR = 0.79, 95% CI = 0.60-1.04, I2 = 76.7%] for type 2 diabetes mellitus, when comparing the highest versus lowest serum potassium levels.
However, the sensitivity analysis did show a significant inverse association between serum potassium and type 2 diabetes mellitus risk [RR = 0.63, 95% CI = 0.52-0.73, I2 = 0%].

The investigators found in random dose-response meta-regression analysis a significantly reduced risk of 17% for type 2 diabetes mellitus [RR = 0.83, 95% CI = 0.73-0.95] per 1 mmol/L increase in serum potassium.

The investigators found in 6 studies involving 112,125 individuals and 4,573 type 2 diabetes mellitus cases, a non-significantly reduced risk of 7% [RR = 0.93, 95% CI = 0.81-1.06, I2 = 0.0%, p = 0.52] for type 2 diabetes mellitus, when comparing the highest versus lowest dietary potassium intake.
The sensitivity analysis did not significantly alter the association between dietary potassium and type 2 diabetes mellitus risk.

The investigators found there was no significant dose-response relationship between dietary potassium and type 2 diabetes mellitus risk [RR for every 1000mg increase dietary potassium per day = 1.00, 95% CI = 0.96-1.05].

The investigators found in 3 studies involving 4,376 individuals and 455 type 2 diabetes mellitus cases, a non-significantly reduced risk of 17% [RR = 0.83, 95% CI = 0.39-1.75, I2 = 73.9%, p = 0.02] for type 2 diabetes mellitus, when comparing the highest versus lowest urinary potassium levels.

The investigators found there was no significant dose-response relationship between urinary potassium levels and type 2 diabetes mellitus risk [RR for 10 mmol increase in urinary potassium per 24 hours = 1.00, 95% CI = 0.95-1.05].

The investigators concluded that serum potassium levels are linearly associated with the risk of type 2 diabetes mellitus, with each 1 mmol/L increase in serum potassium lowering the risk by 17%. However, neither dietary potassium nor urinary potassium shows any association with the risk of type 2 diabetes mellitus.

Original title:
Potassium measurements and risk of type 2 diabetes: a dose-response meta-analysis of prospective cohort studies by Peng Y, Zhong GC, […], Yang G.

Link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725047/

Additional information of El Mondo:
Find more information/studies on type 2 diabetes and potassium right here.
 

Objectives:
The World Health Organization recommends participatory learning and action (PLA) in women’s groups to improve maternal and newborn health, particularly in rural settings with low access to health services. There have been calls to understand the pathways through which this community intervention may affect neonatal mortality. Therefore, this review article (meta-analysis) has been conducted.

The aim of this review article is to examine the effect of women’s groups on key antenatal, delivery and postnatal behaviours in order to understand pathways to mortality reduction.

Study design:
This review article included data from 7 cluster-randomised controlled trials that took place between 2001 and 2012 in rural India (2 trials), urban India (1 trial), rural Bangladesh (2 trials), rural Nepal (1 trial) and rural Malawi (1 trial), with the number of participants ranging between 6,125 and 29,901 live births.

There is a high degree of heterogeneity for effects on most behaviours, possibly due to the limited number of trials involving women’s groups and context-specific effects.

Results and conclusions:
The investigators found overall, women’s groups practising participatory learning and action significantly improved behaviours during and after home deliveries, including: 
-the use of safe delivery kits [during: OR = 2.92, 95% CI = 2.02-4.22, I2 = 63.7% and after: 95% CI = 4.4%-86.2%];
-the use of a sterile blade to cut the umbilical cord [during: OR = 1.88, 95% CI = 1.25-2.82, I2 = 67.6% and after 95% CI = 16.1%-87.5%];
-birth attendant washing hands prior to delivery [during: OR = 1.87, 95% CI = 1.19-2.95, I2 = 79% and after: 95% CI = 53.8%-90.4%];
-delayed bathing of the newborn for at least 24 hours [during: OR = 1.47, 95% CI = 1.09-1.99, I2 =  68.0% and after 29.2%-85.6%] and;
-wrapping the newborn within 10 minutes of delivery [during: OR = 1.27, 95% CI = 1.02-1.60, I2 =  0.0% and after: 95% CI = 0%-79.2%]. Significant because RR of 1 was not found in the 95% CI of 1.02 to 1.60. RR of 1 means no risk/association.
Effects were partly dependent on the proportion of pregnant women attending groups.

The investigators found overall, women’s groups practising participatory learning and action non-significantly improved behaviours during and after home deliveries, for:  
-uptake of antenatal care [during: OR = 1.03, 95% CI = 0.77-1.38, I2 = 86.3% and after: 95% CI = 73.8%-92.8%];
-facility delivery [during: OR = 1.02, 95% CI = 0.93-1.12, I2 = 21.4% and after: 95% CI = 0%-65.8%];
-initiating breastfeeding within 1 hour [during OR = 1.08, 95% CI = 0.85-1.39, I2 = 76.6% and after: 95% CI = 50.9%-88.8%] or;
-exclusive breastfeeding for 6 weeks after delivery [during OR = 1.18, 95% CI = 0.93-1.48, I2 = 72.9% and after: 95% CI = 37.8%-88.2%]. Non-significantly because RR of 1 was found in the 95% CI of 0.93 to 1.48. RR of 1 means no risk/association.

The investigators concluded that women’s groups practising participatory learning and action improve key behaviours on the pathway to neonatal mortality, with the strongest evidence for home care behaviours and practices during home deliveries. A lack of consistency in improved behaviours across all trials may reflect differences in local priorities, capabilities and the responsiveness of health services. Future research could address the mechanisms behind how participatory learning and action improves survival, in order to adapt this method to improve maternal and newborn health in different contexts, as well as improve other outcomes across the continuum of care for women, children and adolescents.  

Original title:
Effects of women’s groups practising participatory learning and action on preventive and care-seeking behaviours to reduce neonatal mortality: A meta-analysis of cluster-randomised trials by Seward N, Neuman M, […], Prost A.

Link:
http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002467

Additional information of El Mondo:
Find more information/studies on food fortification/malnutrition, pregnancy and study design/meta-analysis/significant right here.

Objectives:
Several studies have been conducted on the relationship between tea intake and the risk of osteoporosis. The results from these studies are, however, inconsistent. Therefore, this review article (meta-analysis) has been conducted.

Does tea intake reduce risk of osteoporosis?

Study design:
This review article included 2 prospective cohort studies, 4 cross-sectional studies and 11 case-control studies with 107,819 cases (people with osteoporosis). In the present study, the main symptom of osteoporosis was hip fracture.
10 studies - case-control and cohort studies were all of high quality - were in relative high quality (over 6 stars) with an average NOS score of 7.23.

The heterogeneity in the present review article mainly came from Asia group, female group, prospective cohort study group and case-control study group.

There was no publication bias of the meta-analysis about tea consumption and osteoporosis.

Results and conclusions:
The investigators found for the highest versus the lowest categories of tea consumption a significantly reduced risk of 38% [total OR = 0.62, 95% CI = 0.46-0.83, I2  =  94%, p   0 .01] for osteoporosis. However, when reducing heterogeneity, the overall OR [95% CI = 0.57-0.74, I2 = 30%] was still significant.
Subgroup analysis showed that tea consumption significantly reduced the risk of osteoporosis in all examined subgroups.

The investigators found stratified by categories of osteoporosis, a significantly reduced risk of 26% [OR  =  0.74, 95% BI = 0.63-0.88] for hip fracture.

The investigators found among women a significantly reduced risk of 27% [OR  =  0.73, 95% CI = 0.54-0.99] for osteoporosis.

The investigators concluded that high tea consumption reduces risk of osteoporosis, particularly hip fracture and particularly among women. However, the exact mechanism of the relationship between tea consumption and osteoporosis still needs further research.

Original title:
Association between tea consumption and osteoporosis: A meta-analysis by Sun K, Wang L, [...], Li X.

Link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728912/

Additional information of El Mondo:
Find more information/studies on tea consumption and elderly right here.